Archives
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
AZD0156 and ATM Inhibition in Cancer Research
2026-10-05
AZD0156 is a selective ATM kinase inhibitor used in research on DNA damage response, DNA double-strand break repair, and cancer biology. This overview examines the rationale for ATM inhibition, findings from a high-grade serous ovarian cancer study combining ATM inhibition with fenofibrate, the strength of the available evidence, and the boundaries between supplier claims, cell-model results, and clinical relevance.
-
Metabolic Sensitization of Ferroptosis and Cuproptosis
2026-10-05
The 2024 Chemical Engineering Journal study presents SCu/L, a copper-containing nanosystem designed to inhibit glycolysis and compensatory NAD+ metabolism while increasing tumor-cell susceptibility to ferroptosis and cuproptosis. Its reported effects include depletion of glucose, NAD+, NADPH, and ATP, impaired copper efflux, enhanced regulated cell death, and remodeling of the tumor immune microenvironment.
-
Triiodothyronine (T3) in Thermogenesis Research
2026-10-04
A source-grounded overview of Triiodothyronine and T3 research in metabolic regulation, with emphasis on how the SETD7–adipose thermogenesis study informs—not proves—potential connections to thyroid hormone signaling.
-
CCCP in Mitochondrial Research: Evidence and Limits
2026-10-03
CCCP is a mechanistic mitochondrial proton motive force uncoupler used conceptually to study energy failure, membrane-potential loss, and mitochondrial morphology. This overview separates established mechanism, supplier-reported applications, and findings from a 2025 urine-derived stem-cell Alzheimer’s study, while emphasizing that the study did not test CCCP and that clinical applicability remains unproven.
-
Protein A/G Magnetic Beads: Practical Workflow
2026-10-01
Protein A/G Magnetic Beads (SKU K1305) support Fc-mediated antibody capture for antibody purification, immunoprecipitation, co-immunoprecipitation, and chromatin immunoprecipitation. They are appropriate for research workflows using compatible IgG antibodies, but binding capacity, species or subclass compatibility, wash conditions, and elution recovery should be established experimentally because no universal performance values are provided.
-
Rapamycin and the Translational Logic of mTOR
2026-10-01
Rapamycin and Sirolimus are more than pathway inhibitors: they are experimental tools for connecting mTOR control with protein concentration, cell fate, immune regulation, cancer biology, and mitochondrial disease. This article outlines a translational strategy for using Rapamycin with stronger mechanistic controls and more informative cellular readouts.
-
Triiodothyronine: From Mechanism to Translation
2026-09-30
A translational strategy for using Triiodothyronine (T3) as a controlled mechanistic probe in thyroid hormone signaling, metabolic disorder research, and cell-state engineering, informed by recent advances in spatially concentrated base editing.
-
TH287 MTH1 Inhibitor for Radiosensitization
2026-09-30
TH287 turns oxidized nucleotide stress into a tractable cancer-biology assay, with particular value in schedule-aware radiation studies. A 2026 CRPC study identifies a practical 12-hour drug-to-irradiation interval and connects reduced viability with apoptosis and cell-cycle disruption.
-
TH287 Radiosensitizes Castration-Resistant Prostate Cancer
2026-09-29
A 2026 study found that the MTH1 inhibitor TH287 increased ionizing-radiation sensitivity in PC-3 and DU-145 castration-resistant prostate cancer cells, with the strongest effect when radiation followed TH287 exposure by 12 hours. The work is notable because it treats treatment sequence as a key experimental variable and links the combination to apoptosis and cell-cycle disruption.
-
Serum-Free Cell Freezing Medium: CMC-Ready Cells
2026-09-29
Serum-Free Cell Freezing Medium can help standardize frozen-cell inputs for demanding biotechnology assays. This article connects cryopreservation quality with mRNA-LNP CMC principles, recovery controls, and translational assay design.
-
Calpain, BDNF/TrkB, and Offspring Cognition
2026-09-28
The reference study identifies excessive calpain activation as a mechanistic link between maternal non-obstetric surgery during pregnancy and cognitive impairment in offspring. Its intervention data suggest that postnatal calpain inhibition or TrkB activation can partially restore hippocampal synaptic and neuronal abnormalities, providing a focused framework for neurodevelopmental research.
-
N1-Methylpseudo-UTP for RNA Workflows
2026-09-28
Learn how to use N1-Methylpseudo-UTP in modified RNA synthesis, then assess the resulting transcript in cell-delivery workflows without confusing RNA chemistry with electroporation performance. A nanopore–microfluidic dendritic-cell study offers practical benchmarks for designing those downstream tests.
-
TRIB3 Knockdown Sensitizes ccRCC to Sunitinib
2026-09-27
The study links elevated TRIB3 with poor prognosis in clear cell renal cell carcinoma (ccRCC) and reports that TRIB3 knockdown makes ccRCC cells more responsive to sunitinib. Its central mechanistic finding is that reducing TRIB3 promotes ferroptosis, with the SLC7A11/GPX4 pathway implicated in this response.
-
AZD8055: Practical mTOR Inhibitor Workflow
2026-09-26
AZD8055 is an ATP-competitive mTOR inhibitor for preclinical studies that need to examine mTORC1 and mTORC2 signaling in cells or animal models. It is suited to mechanistic and pharmacodynamic experiments, not conclusions about clinical efficacy; its poor water solubility also requires careful vehicle and precipitation controls.
-
DiscoveryProbe™ Immunology/Inflammation Compound Library
2026-09-25
Learn how to use DiscoveryProbe™ Immunology/Inflammation Compound Library (SKU L1042) to plan immunomodulator screens that distinguish immune activity from nonspecific loss of viability. This scenario-based guide connects assay design, PBMC flow-cytometry evidence, compound handling, and practical supplier-selection criteria.